Literature DB >> 32150445

Temporal hemodynamic changes in a female mouse model of systemic lupus erythematosus.

Elena L Dent1, Erin B Taylor1, Jennifer M Sasser2, Michael J Ryan1,3.   

Abstract

Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disease characterized by circulating autoantibodies, prevalent hypertension, renal injury, and cardiovascular disease. Onset of the disease often occurs in young women of childbearing age. Although kidney involvement is common to patients with SLE, little is known about temporal changes in renal hemodynamic function and its relationship to the pathogenesis of hypertension during autoimmune diseases. We hypothesized that the loss of immunological tolerance and subsequent production of autoantibodies in SLE leads to impaired renal hemodynamic function that precedes the development hypertension. Female NZBWF1 (SLE) mice and female NZW/LacJ (control) mice were instrumented with carotid artery and jugular vein catheters to determine mean arterial pressure (MAP) and glomerular filtration rate, respectively, at ages of 15, 20, 24, 28, 31, and 34 wk. In addition, urinary albumin excretion, blood urea nitrogen, circulating autoantibodies, and glomerulosclerosis were assessed at each age. Levels of circulating autoantibodies are increased between 24 and 28 wk of age in NZBWF1 mice and were significantly greater than in control mice. Glomerular filtration rate was significantly increased at 28 wk of age in NZBWF1 mice followed by a sharp decline at 34 wk of age. NZBWF1 mice had an increase in MAP that occurred by 34 wk of age. These data show that changes in circulating autoantibodies, renal hemodynamic function, and glomerular injury occur in NZBWF1 mice before changes in MAP, suggesting an important mechanistic role for autoimmunity to directly impair renal hemodynamic function and promote the development of hypertension.

Entities:  

Keywords:  autoantibodies; autoimmunity; hypertension; renal hemodynamics; systemic lupus erythematosus

Mesh:

Substances:

Year:  2020        PMID: 32150445      PMCID: PMC7294344          DOI: 10.1152/ajprenal.00598.2019

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  76 in total

1.  Anti-CD3 antibody therapy attenuates the progression of hypertension in female mice with systemic lupus erythematosus.

Authors:  Keisa W Mathis; Erin B Taylor; Michael J Ryan
Journal:  Pharmacol Res       Date:  2017-04-08       Impact factor: 7.658

2.  Blood pressure in a hypertensive mouse model of SLE is not salt-sensitive.

Authors:  Keisa W Mathis; Marcia Venegas-Pont; Chester W Masterson; Katie L Wasson; Michael J Ryan
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-09-14       Impact factor: 3.619

3.  Blood pressure and renal hemodynamic responses to acute angiotensin II infusion are enhanced in a female mouse model of systemic lupus erythematosus.

Authors:  Marcia Venegas-Pont; Keisa W Mathis; Radu Iliescu; William H Ray; Porter H Glover; Michael J Ryan
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-09-07       Impact factor: 3.619

Review 4.  Cardiovascular disease in systemic lupus erythematosus: A comprehensive update.

Authors:  Mayra Giannelou; Clio P Mavragani
Journal:  J Autoimmun       Date:  2017-06-09       Impact factor: 7.094

Review 5.  Understanding the epidemiology and progression of systemic lupus erythematosus.

Authors:  Guillermo J Pons-Estel; Graciela S Alarcón; Lacie Scofield; Leslie Reinlib; Glinda S Cooper
Journal:  Semin Arthritis Rheum       Date:  2009-01-10       Impact factor: 5.532

6.  Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension.

Authors:  L E Bautista; L M Vera; I A Arenas; G Gamarra
Journal:  J Hum Hypertens       Date:  2005-02       Impact factor: 3.012

Review 7.  The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies.

Authors:  Frances Rees; Michael Doherty; Matthew J Grainge; Peter Lanyon; Weiya Zhang
Journal:  Rheumatology (Oxford)       Date:  2017-11-01       Impact factor: 7.580

Review 8.  Autoantibodies and resident renal cells in the pathogenesis of lupus nephritis: getting to know the unknown.

Authors:  Susan Yung; Tak Mao Chan
Journal:  Clin Dev Immunol       Date:  2012-06-14

9.  Immunosuppression With Mycophenolate Mofetil Attenuates Hypertension in an Experimental Model of Autoimmune Disease.

Authors:  Erin B Taylor; Michael J Ryan
Journal:  J Am Heart Assoc       Date:  2017-02-27       Impact factor: 5.501

Review 10.  Serology of Lupus Erythematosus: Correlation between Immunopathological Features and Clinical Aspects.

Authors:  Emanuele Cozzani; Massimo Drosera; Giulia Gasparini; Aurora Parodi
Journal:  Autoimmune Dis       Date:  2014-02-06
View more
  3 in total

1.  AJP-Regulatory, Integrative and Comparative Physiology: Looking Toward the Future.

Authors:  Gina L C Yosten
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2020-05-06       Impact factor: 3.619

Review 2.  Autoimmune-mediated renal disease and hypertension.

Authors:  Erika I Boesen; Rahul M Kakalij
Journal:  Clin Sci (Lond)       Date:  2021-09-17       Impact factor: 6.876

3.  Curcumin attenuates autoimmunity and renal injury in an experimental model of systemic lupus erythematosus.

Authors:  Elena L Dent; Erin B Taylor; Hannah R Turbeville; Michael J Ryan
Journal:  Physiol Rep       Date:  2020-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.